NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
National Cancer Policy Forum; Board on Health Care Services; Institute of Medicine. Policy Issues in the Development and Adoption of Biomarkers for Molecularly Targeted Cancer Therapies: Workshop Summary. Washington (DC): National Academies Press (US); 2015 Jun 1.
Policy Issues in the Development and Adoption of Biomarkers for Molecularly Targeted Cancer Therapies: Workshop Summary.
Show details- MICHAEL A. CALIGIURI (Chair), CEO, James Cancer Hospital & Solove Research Institute, Director, Ohio State University Comprehensive Cancer Center
- PATRICIA A. GANZ (Vice Chair), Professor, University of California, Los Angeles, School of Medicine & Public Health, Division of Cancer Prevention & Control Research, Jonsson Comprehensive Cancer Center
- AMY P. ABERNETHY, Associate Professor of Medicine, Duke University School of Medicine, and Director, Duke Cancer Care Research Program
- LUCILE ADAMS-CAMPBELL, Professor of Oncology, Associate Director for Minority Health and Health Disparities Research, Georgetown University Lombardi Cancer Center
- KENNETH ANDERSON, Kraft Family Professor of Medicine, American Cancer Society Clinical Research Director, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Dana-Farber Cancer Institute
- LOYCE PACE BASS, Health Policy Director, LIVESTRONG Foundation
- MONICA BERTAGNOLLI, Professor of Surgery, Harvard University Medical School
- OTIS BRAWLEY, Chief Medical Officer and Executive Vice President, American Cancer Society
- CARLTON BROWN, Director of Professional Services, Oregon Nurses Association, and Past President, Oncology Nursing Society
- SERGIO CANTOREGGI, Chief Scientific Officer and Global Head of Research and Development, The Helsinn Group
- ROBERT W. CARLSON, CEO, National Comprehensive Cancer Network
- GREGORY CURT, U.S. Medical Science Lead, AstraZeneca
- WILLIAM S. DALTON, CEO, M2Gen Personalized Medicine Institute, Moffitt Cancer Center, and Chair, American Association for Cancer Research Science Policy & Legislative Affairs Committee
- GWEN DARIEN, Executive Vice President, Programs and Services, Cancer Policy Institute, Cancer Support Community
- WENDY DEMARK-WAHNEFRIED, Associate Director for Cancer Prevention and Control, University of Alabama at Birmingham Comprehensive Cancer Center
- JAMES DOROSHOW, Deputy Director, National Cancer Institute
- CAROL A. HAHN, Associate Professor of Radiation Oncology, Duke University Medical Center, Medical Director of Radiation Oncology, Duke Raleigh Hospital, Clinical Affairs and Quality Council Chair, American Society for Radiation Oncology
- LORI HOFFMAN HOGG, Veterans Health Administration National Oncology Clinical Advisor, Office of Nursing Services and Cancer Program Director, Albany Stratton VA Medical Center
- CHARLES HUGH-JONES, Chief Medical Officer, Sanofi North America
- SAMIR N. KHLEIF, Director, Georgia Health Sciences University Cancer Center, Georgia Regents University Cancer Center
- RICHARD A. LARSON, Hematology/Oncology Director, University of Chicago
- MICHELLE M. LE BEAU, Arthur and Marian Edelstein Professor of Medicine, Director, Comprehensive Cancer Center, University of Chicago
- JOSEPH LEVEQUE, Vice President, Head U.S. Medical–Oncology, Bristol-Myers Squibb
- SHARI LING, Deputy Chief Medical Officer, Center for Clinical Standards and Quality, Centers for Medicare & Medicaid Services
- GRETA MASSETTI, Associate Director for Science, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention
- DANIEL R. MASYS, Affiliate Professor, Biomedical Informatics, University of Washington
- MARTIN J. MURPHY, CEO, CEO Roundtable on Cancer
- RICHARD PAZDUR, Director, Office of Oncology and Hematology Products, Food and Drug Administration
- STEVEN PIANTADOSI, Phase One Foundation Endowed Chair and Director, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
- JENNIFER A. PIETENPOL, Director, Vanderbilt-Ingraham Cancer Center, Benjamin F. Byrd, Jr., Professor of Oncology, Professor of Biochemistry, Vanderbilt University
- ANDREW SCHIERMEIER, Senior Vice President, Head of Global Oncology, Merck Serono
- RICHARD SCHILSKY, Chief Medical Officer, American Society of Clinical Oncology
- DEBORAH SCHRAG, Chief, Division of Population Sciences, Professor of Medicine, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
- YA-CHEN TINA SHIH, Professor of Health Economics, Chief, Section of Cancer Economics and Policy, Department of Health Services Research, University of Texas MD Anderson Cancer Center
- ELLEN V. SIGAL, Chair and Founder, Friends of Cancer Research
- ELIZABETH THOMPSON, President and CEO, C-Change
- RALPH WEICHSELBAUM, Daniel K. Ludwig Professor and Chair, Department of Radiation Oncology, Director, Ludwig Center for Metastasis Research, The University of Chicago Medical Center
- GEORGE J. WEINER, Director, Holden Comprehensive Cancer Center, University of Iowa, President, Association of American Cancer Institutes
National Cancer Policy Forum Staff
- SHARYL J. NASS, Forum Director and Director, Board on Health Care Services
- JONATHAN PHILLIPS, Research Associate
- SARA THARAKAN, Research Assistant
- HANNAH DURING, Senior Program Assistant
- PATRICK ROSS, Senior Program Assistant
- PATRICK BURKE, Financial Associate
Footnotes
- 1
Institute of Medicine forums and roundtables do not issue, review, or approve individual documents. The responsibility for the published workshop summary rests with the workshop rapporteurs and the institution.
- NATIONAL CANCER POLICY FORUM - Policy Issues in the Development and Adoption of ...NATIONAL CANCER POLICY FORUM - Policy Issues in the Development and Adoption of Biomarkers for Molecularly Targeted Cancer Therapies
Your browsing activity is empty.
Activity recording is turned off.
See more...